Clinical Trial Update: Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating paclitaxel and pembrolizumab in refractory metastatic urothelial cancer (transitional cell carcinoma) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transitional Cell Carcinoma
• Urothelial Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Transitional Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-10-05